Stock Options and Restricted Stock	3 Months Ended
Mar. 31, 2020
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock Options and Restricted Stock	Note 2. Stock Options and Restricted Stock As of March 31, 2020, the Company has two equity incentive plans: the AMERISAFE Non-Employee Director Restricted Stock Plan (the “Restricted Stock Plan”) and the AMERISAFE 2012 Equity and Incentive Compensation Plan (the “2012 Incentive Plan”). In connection with the approval of the 2012 Incentive Plan by the Company’s shareholders, no further grants were made under the AMERISAFE 2005 Incentive Plan. There are no outstanding options or restricted stock awards under the 2005 Incentive Plan. See Note 12 to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2019 for additional information regarding the Company’s incentive plans. During the three months ended March 31, 2020, the Company issued 201 shares of restricted common stock to non-employee directors. The market value of these shares totaled $13.7 thousand. During the three months ended March 31, 2019, the Company issued no shares of common stock. During the three months ended March 31, 2020, there were no exercises of options to purchase common stock. During the three months ended March 31, 2019, options to purchase 5,000 shares of common stock were exercised. In connection with these exercises, the Company received $19.8 thousand of stock option proceeds. The Company had no stock options outstanding as of March 31, 2020. The Company recognized share-based compensation expense of $0.8 million in the quarter ended March 31, 2020 and $0.6 million for the same period in 2019.

Stock Options and Restricted Stock

3 Months Ended

Mar. 31, 2020

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Note 2. Stock Options and Restricted Stock

As of March 31, 2020, the Company has two equity incentive plans: the AMERISAFE Non-Employee Director Restricted Stock Plan (the “Restricted Stock Plan”) and the AMERISAFE 2012 Equity and Incentive Compensation Plan (the “2012 Incentive Plan”). In connection with the approval of the 2012 Incentive Plan by the Company’s shareholders, no further grants were made under the AMERISAFE 2005 Incentive Plan. There are no outstanding options or restricted stock awards under the 2005 Incentive Plan. See Note 12 to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2019 for additional information regarding the Company’s incentive plans.

During the three months ended March 31, 2020, the Company issued 201 shares of restricted common stock to non-employee directors. The market value of these shares totaled $13.7 thousand. During the three months ended March 31, 2019, the Company issued no shares of common stock.

During the three months ended March 31, 2020, there were no exercises of options to purchase common stock. During the three months ended March 31, 2019, options to purchase 5,000 shares of common stock were exercised. In connection with these exercises, the Company received $19.8 thousand of stock option proceeds. The Company had no stock options outstanding as of March 31, 2020.

The Company recognized share-based compensation expense of $0.8 million in the quarter ended March 31, 2020 and $0.6 million for the same period in 2019.